LongevityMedium Risk

Teriparatide

Also known as: Forteo, PTH 1-34, Parathyroid Hormone 1-34

Half-life:: ~1 hour

Administration Routes

subcutaneous injection

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

FDA-approved parathyroid hormone fragment for severe osteoporosis. The only anabolic bone treatment (builds new bone vs. just preventing loss). Used by longevity physicians for bone density optimization.

Primary Research Areas

bone formation
bone density increase
osteoporosis reversal
fracture risk reduction

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Prescription OnlyFDA Approved

FDA-approved parathyroid hormone 1-34 analog. Forteo (NDA 021318, Nov 2002) for osteoporosis. Biosimilar Bonsity (NDA 210842, Jan 2020) also approved. Prescription only.

Effective: November 26, 2002View FDA source →

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Teriparatide

No active associated providers listed yet.